Logo of bmcidBioMed Centralsearchsubmit a manuscriptregisterthis articleBMC Infectious Diseases
BMC Infect Dis. 2007; 7: 76.
Published online 2007 Jul 13. doi:  10.1186/1471-2334-7-76
PMCID: PMC1939851

Influenza pandemic intervention planning using InfluSim: pharmaceutical and non- pharmaceutical interventions



Influenza pandemic preparedness plans are currently developed and refined on national and international levels. Much attention has been given to the administration of antiviral drugs, but contact reduction can also be an effective part of mitigation strategies and has the advantage to be not limited per se. The effectiveness of these interventions depends on various factors which must be explored by sensitivity analyses, based on mathematical models.


We use the freely available planning tool InfluSim to investigate how pharmaceutical and non-pharmaceutical interventions can mitigate an influenza pandemic. In particular, we examine how intervention schedules, restricted stockpiles and contact reduction (social distancing measures and isolation of cases) determine the course of a pandemic wave and the success of interventions.


A timely application of antiviral drugs combined with a quick implementation of contact reduction measures is required to substantially protract the peak of the epidemic and reduce its height. Delays in the initiation of antiviral treatment (e.g. because of parsimonious use of a limited stockpile) result in much more pessimistic outcomes and can even lead to the paradoxical effect that the stockpile is depleted earlier compared to early distribution of antiviral drugs.


Pharmaceutical and non-pharmaceutical measures should not be used exclusively. The protraction of the pandemic wave is essential to win time while waiting for vaccine development and production. However, it is the height of the peak of an epidemic which can easily overtax general practitioners, hospitals or even whole public health systems, causing bottlenecks in basic and emergency medical care.


The recent spread of highly pathogenic avian influenza from Asia to Europe and the transmission to humans has intensified concerns over the emergence of a novel strain of influenza with pandemic potential. While still being in an inter-pandemic stage, nations plan for pandemic contingency following recommendations of the WHO [1,2]. National influenza preparedness plans are constantly being refined, aiming to mitigate the effects of pandemic influenza on a national, regional and local level. Even in the absence of a pandemic strain, seasonal influenza causes substantial morbidity and mortality [3]. Seasonal outbreaks put pressure on general practitioners and strain hospital resources, leading to bottlenecks in outpatient treatment and hospital admission capacities.

Various intervention strategies reduce the impact of influenza on individuals and public health systems. In inter-pandemic phases, vaccination is the most important tool to reduce morbidity and mortality, but a potent vaccine will probably not be generally available in the initial phase of a pandemic [4]. Other control strategies like pharmaceutical (antiviral) [5,6] and non-pharmaceutical interventions (reduction of contact rates) [7,8] will have to be implemented.

The use of antiviral drugs during a pandemic seems to be the treatment of choice at present [9-12], but not all countries can afford stockpiling enough drugs. Furthermore, concerns about the over-reliance of a "pharmaceutical solution" have been expressed [13]. An epidemic can also be mitigated by reducing contact rates in the general population and by decreasing the infectivity of cases [9]. Such reductions can be achieved by measures like quarantine and case isolation [14], closing day care centres and schools, cancelling mass gathering events, voluntary self isolation and general behavioural changes in public and increasing social distance [8].

The effectiveness of such interventions depends on various factors which must be prospectively explored by sensitivity analyses, based on mathematical models. Here, we use the freely available Java applet InfluSim [15] to investigate how effectively pharmaceutical and non-pharmaceutical interventions contribute to mitigate an influenza pandemic while vaccines are not available. In particular, we examine how intervention delays determine the course of a pandemic and constrict the success of interventions.


InfluSim is a deterministic compartment model based on a system of over thousand differential equations which extend the classic SEIR model by clinical and demographic parameters relevant for pandemic preparedness planning. Details of the simulation and a discussion of the standard parameter values have been described previously [15]; a summarizing description of the model is provided in the Appendix. The program and its source code are publicly available [16] to offer transparency and reproducibility. The simulation produces time courses and cumulative numbers of influenza cases, outpatient visits, applied antiviral treatment doses (neuraminidase inhibitors), hospitalizations, deaths and work days lost due to sickness, all of which may be associated with financial loss. The analyses presented here are based on InfluSim 2.0, using demographic and public health parameters which represent the situation in Germany in 2006. Interventions include antiviral treatment, isolation of patients, social distancing measures and the closing of day care centres and schools as well as cancelling mass gathering events.

Using the standard set of InfluSim parameters (freely accessible from [15]), about one third of all infected individuals is expected to become severely ill and to seek medical help. Patients seeking medical help will be referred to as "outpatients" throughout this paper. An exponential distribution is used to model the delay between onset of symptoms and seeking medical help; on average, patients visit a doctor after 24 hours. If a patient seeks medical help within 48 hours after onset of symptoms, he or she is given antiviral treatment unless the stockpile of antivirals is exhausted. Antiviral treatment reduces the duration and degree of infectivity of the case and the number of hospitalizations (Table (Table1)1) [17]. For more detailed descriptions see [15] or the Appendix.

Table 1
Antiviral treatment schedule and effects

Non-pharmaceutical interventions examined in this paper are contact reduction measures and the isolation of cases. The latter effectively leads to reduced contact rates between individuals, too. In the scenarios presented below, we assume that everybody in the population avoids a given percentage of contacts (e.g. by improved hygiene, wearing masks, or behavioural changes) and that sick patients are isolated which reduces the contact rates of moderately sick, severely sick (but non-hospitalized) and hospitalized cases by 10%, 20% and 30%, respectively. Further interventions which comprise the closing of day care centres and schools, and the cancelling of mass gathering events will be examined in detail in a separate paper.


Assuming a basic reproduction number of R0 = 2.5 and using the standard parameter set of InfluSim [15], an epidemic in a population of 100,000 individuals reaches the peak about 40 days after introduction of the infection and is practically over three weeks thereafter if no interventions are performed (Figure (Figure1).1). During the whole epidemic, 87% of the population become infected, 29% seek medical help, 0.7% are hospitalized and 0.2% die. Figure Figure11 shows how pharmaceutical and non-pharmaceutical interventions can mitigate this scenario. Contact reduction by isolation of cases alone (see Appendix), protracts the peak of the epidemic by about one week. Distribution of antivirals or additional contact reduction measures delay the epidemic by approximately 10 days and are hardly sufficient to provide a substantial delay. A combination of antiviral treatment, isolation of cases and social distancing in the general population seems to be necessary to delay the epidemic in the order of weeks. This example furthermore shows that an efficient mitigation of the epidemic is not necessarily associated with a significant reduction in the number of infections. For information on the proportions of infected people and outpatients see the legends to the Figures.

Figure 1
Comparison of different intervention schemes. Number of outpatients expected during a pandemic wave in a population of 100,000 citizens. Parameter values are based on the InfluSim standard configuration [15] with R0 = 2.5, except those listed at the end ...

Intervention with antivirals

The mitigating effect of antivirals strongly depends on the onset of their distribution (Figure (Figure2).2). Antivirals can delay the epidemic if distributed very early while few cases exist in the population. Late distribution of antivirals (e.g. starting on day 30) leads to the paradoxical effect that the stockpile is exhausted even quicker compared to early distribution (shaded areas und the curves in Figure Figure2).2). Additionally, the mitigating effect of the intervention drastically diminishes and benefits are restricted to lowering the peak of the epidemic. Unrestricted availability of drugs (grey curves in Figure Figure2)2) still leads to an epidemic because (i) asymptomatic and moderately sick cases are not eligible for treatment, (ii) patients visit a doctor on average 24 hours after onset of symptoms while already being highly infectious and (iii) antivirals cannot fully prevent infectivity.

Figure 2
Onset and sustainability of antiviral intervention. Number of outpatients expected during a pandemic wave, varied by day of onset when antivirals come into operation. Parameter values are based on the InfluSim standard configuration [15] with R0 = 2.5, ...

Figure Figure33 extends these considerations by showing epidemic curves where all clinically ill patients are treated with antiviral drugs until the stockpile is exhausted. The mitigating effect of antiviral distribution is weakly influenced by the amounts of available antivirals, but is strongly determined by the onset of administration. The model suggests that even a small stockpile of antivirals can protract the peak of the epidemic if distributed very early while few cases exist in the population (Figure (Figure3A).3A). In contrast, the mitigating effect becomes negligible, if antivirals are distributed with delay (Figure (Figure3B).3B). Independent of the delay in the distribution of antivirals, their quantitative availability affects only the height of the peak of the epidemic, but hardly the mitigation of the epidemic (Figure 3A, B). For considerations into the final size of the epidemic see below. In summary, delaying the epidemic depends on early action, whereby lowering the peak depends on the quantitative availability of antivirals.

Figure 3
Intervention with limited amounts of antivirals. Number of outpatients expected during a pandemic wave, varied by the availability of antivirals. Parameter values are based on the InfluSim standard configuration [15] with R0 = 2.5, except those listed ...

Intervention through contact reduction

Contact reduction measures, comprising social distancing and the isolation of cases, can be an effective part of mitigation strategies; they have the advantage over antiviral treatment to be not limited per se, i.e. they can be continued for a sufficiently long period of time. Figure Figure44 examines the effect of isolation of cases and social distancing measures (see figure caption for details) in the absence of antiviral treatment. The peak of the epidemic is protracted by about 1 day for every percent of contact reduction if this intervention starts immediately after the introduction of the infection. Thus, a peak shift is not only possible by early action, but also by the degree of contact reduction. If contact reduction is initiated later, the peak shift diminishes, but the proportionality remains. For example, if the intervention starts three weeks after the introduction of infection, the peak of the epidemic is only mitigated by about half a day per 1% contact reduction (Figure (Figure4B).4B). Premature cessation of contact reduction measures restores the infection rates to the pre-intervention values which fuels the epidemic. It can lead to a delayed course and a higher total number of infections, involving a plateau or even a second peak of the epidemic (Figure (Figure4C4C).

Figure 4
Effects of contact reduction measures. Number of outpatients expected during a pandemic wave if contact reduction measures are implemented additionally to the isolation of cases. Parameter values are based on the InfluSim standard configuration [15] with ...

Combined intervention scheme

The preceding examples with interventions based on antivirals or contact reduction alone yielded peak delays only in the order of weeks, whereas months may be required for vaccine development and production, demanding for a combined intervention scheme (Figure (Figure5).5). We examine an optimistic scenario where antivirals are distributed immediately after the infection is introduced (dark bars in Figure Figure5),5), while varying the onset of social distancing measures. The antiviral stockpile lasts longer if social distancing measures are initiated earlier (pale bars in Figure Figure5).5). Immediate initiation of contact reduction can protract the epidemic by months, whereas a delayed initiation leads to a plateau in the epidemic curve at a time when antivirals are used up.

Figure 5
Combined intervention scheme. Number of outpatients expected during an influenza pandemic if antiviral distribution and contact reduction measures are implemented additionally to the isolation of cases. Parameter values are based on the InfluSim standard ...

Cumulative number of infections and outpatients

Without interventions, Ni = 87% of the population become infected during the course of the epidemic and the cumulative number of outpatients reaches No = 29%, reflecting the assumption that approximately one third of infected individuals becomes sufficiently sick to seek medical help. These outcomes remain surprisingly stable even for interventions assuming optimistic resources (cf. footnotes to Figures Figures1,1, ,2,2, ,3,3, ,4,4, ,5).5). For instance, immediate and unlimited availability of antivirals reduces these fractions only to Ni = 72% and No = 24% (Figure (Figure2).2). This minor effect has three reasons: only about one third of cases seeks medical help and will receive antiviral treatment, many infections are passed on before cases seek medical help and antiviral treatment does not fully prevent further transmission. These disadvantages do not apply to contact reduction measures. For instance, a reduction of 20% of contacts reduces these fractions to Ni = 68% and No = 22% (Figures 4A, B). A combination of antiviral treatment and contact reduction can further reduce these values to Ni = 53% and No = 18% (Figure (Figure55).

Uncertainty in the parameter values

In the preceding analyses it was assumed that parameter values are precisely known; in a real world scenario, however, uncertainty arises from biological variability, stochastic influences, heterogeneities, etc. We illustrate with a concluding example to which extent simulated epidemics are affected by uncertainty in the parameter values. As shown in Figure Figure6,6, epidemics can be highly variable, although only four parameters have been varied within moderate ranges. Varying more parameters would further increase this variability.

Figure 6
Sensitivity analysis considering uncertainty of parameter values. Variability in epidemic curves (large plot) and the distribution of the cumulative number of outpatients (inset), originating from the uncertainty in four parameters (right panel). Parameter ...

For the interventions and parameter variations considered, the cumulative number of outpatients ranges from a few thousand to over twenty thousand (see inset in Figure Figure6).6). Among the four parameters, R0 is the strongest predictor of the number of outpatients (analysis not shown) as it strongly determines how quickly antivirals become exhausted. In two out of 1,000 simulations the randomly chosen parameter combinations involved values for R0 around 1.8 which led to very minor outbreaks given the intervention scheme. The cumulative number of outpatients escalates when antiviral stockpiles become exhausted while the proportion of susceptibles is still large enough to allow for further propagation of infectives. In this case, the epidemic curve proceeds with a second wave or a plateau.


With pandemic influenza, we have to "expect the unexpected" [18]. Historical reports frequently mention the surprising speed at which a pandemic wave travels through the population [19-21]. Predicting the course of a future pandemic which will be caused by a virus with unknown characteristics is based on substantial uncertainties and we must rely on sensitivity analyses, performed with mathematical models like InfluSim.

Because of the short serial interval of influenza, timely action is essential. Different control measures must be regarded as complementary and not as competing. Neither antiviral treatment nor non-pharmaceutical measures should be used exclusively to mitigate a pandemic influenza wave.


Infectious disease models have suggested that an upcoming influenza epidemic with a low basic reproduction number might be contained at the source through targeted use of antiviral drugs [9,12]. The published scenarios concern WHO phases 4 and 5 (inter-pandemic alert period) and assume that an outbreak starts in a rural area with low population density. It can be expected that the pandemic virus will be introduced into Europe and the US after a local epidemic (i.e. in WHO phase 6). Community-based prophylaxis, however, is of limited use for several reasons. Under a high prevalence of infection in phase 6, a wide distribution requires an enormous number of antiviral courses; with available stockpiles, it will be virtually impossible to locally contain the pandemic with targeted antiviral prophylaxis. Development of resistance, limited production capacities and extremely high costs are further limitations of this strategy, so that population-wide prophylaxis has not been recommended by the WHO for the final phase of the pandemic [1].

The discussion of pandemic influenza preparedness planning has frequently focussed on the amounts of drugs to be stockpiled and to whom and when they should be supplied [22]. Even if the currently stockpiled antiviral drugs will be fully effective against the pandemic strain, their use may not be able to sufficiently prevent the spread of influenza because (i) transmission of the infection may occur before the onset of clinical symptoms (as assumed in the InfluSim model) [23], (ii) asymptomatic and moderately sick cases [6] are usually not treated despite contributing to transmission, and (iii) the occurrence of cases with influenza-like illness caused by other pathogens may lead to an accelerated depletion of the antiviral stockpile. Likewise, moderately sick cases or even healthy people may seek medical help and succeed in receiving antiviral treatment which would further deplete the stockpile. These factors reduce the efficacy of pharmaceutical control measures [24], indicating the demand of extending this strategy by non-pharmaceutical intervention measures.

Especially if antivirals are limited, they should be supplied as early as possible. If their distribution is delayed, cases become so abundant that resources will quickly be exhausted without having much impact on the spread of the disease (Figures (Figures22 and and3).3). This confirms that the amount of antivirals needed strongly depends on the number of infections that are present when the intervention is initiated [25]. If antiviral drugs are extremely limited, they should be used to preferably treat severe cases that need hospitalization. Although this has practically no effect on the pandemic wave per se, it helps to reduce the death toll in the population (results not shown).

Contact reduction

Rather than relying on a pharmaceutical solution, pandemic preparedness should also involve non-pharmaceutical measures (see above). Early self-isolation and social distancing measures can be highly effective, as shown for the SARS epidemic [26]: after the WHO's global alert and the implementation of massive infection control measures, the effective reproduction numbers in Hong Kong, Vietnam, Singapore and Canada fell below unity. Rigorous social distancing measures in the entire population, however, will tax the social and economic structure and the population may not be willing or able to reduce contacts during the whole course of a pandemic wave.

For Figure Figure5,5, we assumed that contact reduction measures (e.g. improved hygiene, wearing masks, or behavioural changes) could add up to reduce contacts by 20%. Studies on the SARS outbreak suggest some preventative effect of wearing masks [27-29], but compliance, availability of masks and their effectiveness against influenza infection remain unknown factors. Stockpiling surgical masks for the population results in exorbitant high numbers and may not be feasible [30] and individual stockpiling may be impossible due to economic limitations, especially in crisis situations. Since the specific effects of such behavioral changes remain uncertain, we modeled their contribution as a general reduction in contact rates.

In contrast to SARS, we will not be able to rely on isolating hospitalized cases when a new influenza pandemic emerges. Using the standard parameter settings of InfluSim, we expect only a total of 0.7% of the population to be hospitalized. Even for the worst case scenario of the US Pandemic Preparedness Plan, where this value may be up to ten times larger [31], the wide majority of infected individuals is never hospitalized. With influenza, we have to rely on self-isolation of moderately sick cases and of bed-ridden patients who stay at home. As these cases form the majority of infections and exert the highest force of infection, even a moderate reduction of contacts between them and the general population can substantially change the pandemic wave.


Time is of the essence when controlling infectious diseases that spread at high speed and thus, interventions are most effective in the beginning when only few people are infected. Only a timely application of antiviral drugs (even with limited supplies) and a quick implementation of contact reduction measures will notably protract the peak of the epidemic and substantially reduce its height in a pandemic influenza wave. Whereby the protraction of the pandemic wave is essential to win time while waiting for vaccine development and production, it is the height of the peak of a pandemic wave which can easily overtax general practitioners as well as hospitals and whole public health systems, and can lead to dangerous bottlenecks in basic and emergency medical care. Vaccinating a small fraction of the population with a pre-pandemic vaccine would have a similar effect on the course of the epidemic as reducing the basic reproduction number by the percentage of immunized individuals (e.g. by 10%).

The sensitivity analyses at the end of the Results section shows that the planning of intervention strategies must not only be based on single parameter values, but must also address their variability. More detailed analyses into this will be presented in a subsequent publication. Mathematical models like InfluSim should not only be used to predict a specific outcome, but also to explore best and worst case scenarios.

Competing interests

The author(s) declare that they have no competing interests.

Authors' contributions

ME developed the model, MS designed the software, HPD wrote the manuscript and SOB and IP formulated the public health requirements of the software. All authors read and approved the final manuscript.

Appendix: brief description of the transmission dynamics of InfluSim

For a detailed description of InfluSim see Eichner M, Schwehm M, Duerr HP, Brockmann SO. The influenza pandemic preparedness planning tool InfluSim. BMC Infect Dis. 2007 Mar 13;7:17.

General description

InfluSim is a deterministic compartment model based on a system of over 1,000 differential equations which extend the classic SEIR model by clinical and demographic parameters relevant for pandemic preparedness planning. It allows for producing time courses and cumulative numbers of influenza cases, outpatient visits, applied antiviral treatment doses, hospitalizations, deaths and work days lost due to sickness, all of which may be associated with economic aspects. The software is programmed in Java and open access [16], it operates platform independent and can be executed on regular desktop computers.

Model description

The model structure of InfluSim is represented by Figure Figure7,7, with descriptions given below.

Figure 7
Model structure of InfluSim 2.0. Transitions from each compartment depend on age; transitions from the exposed (E) state into diseased states (A, M, V, X) additionally depend on the risk group which is assigned to susceptible (S) individuals at birth. ...

Natural history of disease

Susceptible individuals (S) are infected at a rate which depends on their age and on the interventions applied at the current time. Infected individuals (E) incubate the infection for a mean duration of 1.9 days. To obtain a realistic distribution of this duration, the incubation period is modelled in 7 stages yielding a gamma distributed incubation period with a coefficient of variation of 37.8%. The last 2 incubation stages are regarded as early infectious period during which patients may already spread the infection. This accounts for an average time of about half a day for the standard set of parameters.

After passing through the last incubation stage, infected individuals become fully infective and a fraction of them develops clinical symptoms (Figure (Figure8A).8A). The course of disease depends on their age and risk group: one third remains asymptomatic (A), one third shows a moderate course of disease (M, "moderately sick") and the remaining third a severe course of disease (V, "very sick"); a small fraction of the latter third shows an extremely severe course of disease (X, "extremely sick") and needs hospitalization. The rationale for distinguishing extremely sick cases is that only these can die from the disease and need to be hospitalized; in all other aspects, both groups of severe cases are identical. The period of infectivity is gamma distributed and depends on the course of the disease and on the age of the case. To allow for an infectivity which changes over the course of disease, we apply weighting factors which depend on the stage of infectivity. Our standard value results in an infectivity which is highest immediately after onset of symptoms and which declines in a geometric progression over time (Figure (Figure8B8B).

Figure 8
Time-course of symptoms and infectivity. Symptoms and infectivity dependent on time, for cases with a severe (V), a moderate (M) or an asymptomatic (A) course of disease (treatment is indicated by subscripts). A: Fraction of symptomatic cases among all ...

Severe cases seek medical help on average one day after onset of symptoms, whereby the waiting time until visiting a doctor is exponentially distributed. Very sick and extremely sick patients who visit a doctor may be offered antiviral treatment. Very sick patients are advised to withdraw to their home (W) until the disease is over whereas extremely sick cases are immediately hospitalized (H). Death rates of extremely sick and hospitalized cases are age-dependent. Whereas asymptomatic and moderately sick patients who have passed their duration of infectivity are considered healthy immunes, very sick and extremely sick patients first become convalescent before they resume their ordinary life (gamma distributed with a mean of 5 days and coefficient of variation of 33.3%). Fully recovered patients who have passed their period of convalescence join the group of healthy immunes; working adults will return to work, and children again visit day care centres or schools.


Antiviral treatment: Severe and extremely severe cases who visit the doctor within at most two days after onset of symptoms are offered antiviral treatment, given that its supply has not yet been exhausted. Antiviral treatment reduces the patients' infectivity by 80 percent, the duration of being diseased by 25%, and the risk of hospitalization by 50 percent. Extremely sick patients, whose hospitalization is prevented by treatment, are sent home and join the group of treated very sick patients.

Social distancing measures: Contact rates in the general population can be reduced by increasing "social distance", by closing schools and day care centres, by cancelling mass gathering events, or by behavioural changes.

Isolation of cases: Isolation of cases reduces their contact rates. Contacts are not necessarily reduced by 100%, but between 0 and 100%, as specified by the user. Our standard scenario considers reductions of 10%, 20% and 30% for moderately sick cases, very sick cases (at home) and extremely sick cases (hospitalized), respectively.

Mixing matrix, basic reproduction number and force of infection

For the mixing of the age classes, we employ a "who-acquires-infection-from-whom matrix" (WAIFW matrix) which gives the relative frequency of contacts of infective individuals by age. InfluSim assumes bi-directional contacts (e.g. children have the same total number of contacts with adults as adults with children). In order to match the user-specified basic reproduction number R0, the disease-specific infectivity and the durations of infectivity in this matrix must be incorporated, resulting in the next generation matrix. This matrix is multiplied with a scaling factor chosen such its largest eigenvalue is equal to the chosen value of R0. The force of infection is given as the product of the number of infective individuals and the corresponding age-dependent contact rates.

Initial values

At the start of the simulation, one infection is introduced into the fully susceptible population. To avoid bias between simulations, the initial infection is distributed over all age and risk classes.

Pre-publication history

The pre-publication history for this paper can be accessed here:



This work has been supported by EU projects SARScontrol (FP6 STREP; contract no. 003824) (HPD) and INFTRANS (FP6 STREP; contract no. 513715) (MS), the MODELREL project, funded by DG SANCO (no. 2003206 – SI 2378802) (MS, ME), and by the German Ministry of Health (MS, ME).


  • WHO WHO global influenza preparedness plan. http://www.who.int/csr/resources/publications/influenza/GIP_2005_5Eweb.pdf
  • Mounier-Jack S, Coker RJ. How prepared is Europe for pandemic influenza? Analysis of national plans. Lancet. 2006;367:1405–1411. doi: 10.1016/S0140-6736(06)68511-5. [PubMed] [Cross Ref]
  • Dushoff J, Plotkin JB, Viboud C, Earn DJ, Simonsen L. Mortality due to influenza in the United States--an annualized regression approach using multiple-cause mortality data. Am J Epidemiol. 2006;163:181–187. doi: 10.1093/aje/kwj024. [PubMed] [Cross Ref]
  • Webby RJ, Webster RG. Are we ready for pandemic influenza? Science. 2003;302:1519–1522. doi: 10.1126/science.1090350. [PubMed] [Cross Ref]
  • Gani R, Hughes H, Fleming D, Griffin T, Medlock J, Leach S. Potential impact of antiviral drug use during influenza pandemic. Emerg Infect Dis. 2005;11:1355–1362. [PMC free article] [PubMed]
  • Longini IM, Jr., Halloran ME, Nizam A, Yang Y. Containing pandemic influenza with antiviral agents. Am J Epidemiol. 2004;159:623–633. doi: 10.1093/aje/kwh092. [PubMed] [Cross Ref]
  • Bell DM. Non-pharmaceutical interventions for pandemic influenza, international measures. Emerg Infect Dis. 2006;12:81–87. [PMC free article] [PubMed]
  • Bell DM. Non-pharmaceutical interventions for pandemic influenza, national and community measures. Emerg Infect Dis. 2006;12:88–94. [PMC free article] [PubMed]
  • Ferguson NM, Cummings DA, Cauchemez S, Fraser C, Riley S, Meeyai A, Iamsirithaworn S, Burke DS. Strategies for containing an emerging influenza pandemic in Southeast Asia. Nature. 2005;437:209–214. doi: 10.1038/nature04017. [PubMed] [Cross Ref]
  • Ferguson NM, Cummings DA, Fraser C, Cajka JC, Cooley PC, Burke DS. Strategies for mitigating an influenza pandemic. Nature. 2006;442:448–452. doi: 10.1038/nature04795. [PubMed] [Cross Ref]
  • Germann TC, Kadau K, Longini IM, Jr., Macken CA. Mitigation strategies for pandemic influenza in the United States. Proc Natl Acad Sci U S A. 2006;103:5935–5940. doi: 10.1073/pnas.0601266103. [PMC free article] [PubMed] [Cross Ref]
  • Longini IM, Jr., Nizam A, Xu S, Ungchusak K, Hanshaoworakul W, Cummings DA, Halloran ME. Containing pandemic influenza at the source. Science. 2005;309:1083–1087. doi: 10.1126/science.1115717. [PubMed] [Cross Ref]
  • Jefferson T, Demicheli V, Rivetti D, Jones M, Di Pietrantonj C, Rivetti A. Antivirals for influenza in healthy adults: systematic review. Lancet. 2006;367:303–313. doi: 10.1016/S0140-6736(06)67970-1. [PubMed] [Cross Ref]
  • Eichner M. Case isolation and contact tracing can prevent the spread of smallpox. Am J Epidemiol. 2003;158:118–128. doi: 10.1093/aje/kwg104. [PubMed] [Cross Ref]
  • Eichner M, Schwehm M, Duerr HP, Brockmann SO. The influenza pandemic preparedness planning tool InfluSim. BMC Infect Dis. 2007;7:17. doi: 10.1186/1471-2334-7-17. [PMC free article] [PubMed] [Cross Ref]
  • Eichner M, Schwehm M. InfluSim http://www.influsim.info [PubMed]
  • Kaiser L, Wat C, Mills T, Mahoney P, Ward P, Hayden F. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med. 2003;163:1667–1672. doi: 10.1001/archinte.163.14.1667. [PubMed] [Cross Ref]
  • Shortridge KF. Influenza pandemic preparedness: gauging from EU plans. Lancet. 2006;367:1374–1375. doi: 10.1016/S0140-6736(06)68512-7. [PubMed] [Cross Ref]
  • Frost WH. The epidemiology of influenza. JAMA : the journal of the American Medical Association. 1919;73:313–318.
  • Collins SD. The influenza epidemic of 1928-1929 with comparative data for 1918-1919. American journal of public health and the nation's health. 1930;12:119–129. [PMC free article] [PubMed]
  • Mills CE, Robins JM, Lipsitch M. Transmissibility of 1918 pandemic influenza. Nature. 2004;432:904–906. doi: 10.1038/nature03063. [PubMed] [Cross Ref]
  • WHO WHO Guidelines on the Use of Vaccines and Antivirals during Influenza Pandemics http://www.who.int/vaccine_research/diseases/influenza/WHO_guidelines_on_the_use_of_vaccines_and_antivirals.pdf [PubMed]
  • Hayden FG, Fritz R, Lobo MC, Alvord W, Strober W, Straus SE. Local and systemic cytokine responses during experimental human influenza A virus infection. Relation to symptom formation and host defense. J Clin Invest. 1998;101:643–649. [PMC free article] [PubMed]
  • Fraser C, Riley S, Anderson RM, Ferguson NM. Factors that make an infectious disease outbreak controllable. Proc Natl Acad Sci U S A. 2004;101:6146–6151. doi: 10.1073/pnas.0307506101. [PMC free article] [PubMed] [Cross Ref]
  • Arino J, Brauer F, van den Driessche P, Watmough J, Wu J. Simple models for containment of a pandemic. Journal of the Royal Society Interface. 2006;3:453–457. doi: 10.1098/rsif.2006.0112. [PMC free article] [PubMed] [Cross Ref]
  • Wallinga J, Teunis P. Different epidemic curves for severe acute respiratory syndrome reveal similar impacts of control measures. Am J Epidemiol. 2004;160:509–516. doi: 10.1093/aje/kwh255. [PubMed] [Cross Ref]
  • Nishiura H, Kuratsuji T, Quy T, Phi NC, Van Ban V, Ha LE, Long HT, Yanai H, Keicho N, Kirikae T, Sasazuki T, Anderson RM. Rapid awareness and transmission of severe acute respiratory syndrome in Hanoi French Hospital, Vietnam. Am J Trop Med Hyg. 2005;73:17–25. [PubMed]
  • Wu J, Xu F, Zhou W, Feikin DR, Lin CY, He X, Zhu Z, Liang W, Chin DP, Schuchat A. Risk factors for SARS among persons without known contact with SARS patients, Beijing, China. Emerg Infect Dis. 2004;10:210–216. [PMC free article] [PubMed]
  • Lau JT, Tsui H, Lau M, Yang X. SARS transmission, risk factors, and prevention in Hong Kong. Emerg Infect Dis. 2004;10:587–592. [PMC free article] [PubMed]
  • Pourbohloul B, Meyers LA, Skowronski DM, Krajden M, Patrick DM, Brunham RC. Modeling control strategies of respiratory pathogens. Emerging Infectious Diseases. 2005;11:1249–1256. [PMC free article] [PubMed]
  • PandemicPlan_US U.S. Department of Health & Human Services Pandemic Influenza Plan. http://www.hhs.gov/pandemicflu/plan/

Articles from BMC Infectious Diseases are provided here courtesy of BioMed Central
PubReader format: click here to try


Save items

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • Compound
    PubChem chemical compound records that cite the current articles. These references are taken from those provided on submitted PubChem chemical substance records. Multiple substance records may contribute to the PubChem compound record.
  • MedGen
    Related information in MedGen
  • PubMed
    PubMed citations for these articles
  • Substance
    PubChem chemical substance records that cite the current articles. These references are taken from those provided on submitted PubChem chemical substance records.

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...